Back

Do we need PCSK9 inhibitors in post-MI patients? CON

27 August 2017 (11:35 - 11:55)
Organised by:
Congress Presentation Part of: Do we need PCSK9 inhibitors in post-MI patients? Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Heinz Drexel

Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch (Austria)

7 More presentations in this session

Presentation thumbnail
Opening question.
Slides Video
Presentation thumbnail
Positioning of the topic - The PCSK9 story .. so far
Professor F. Mach (Geneva, CH)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? PRO
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO
Professor M. Sabatine (Boston, US)
Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON
Professor H. Drexel (Feldkirch, AT)
Video

Access the full session

Session thumbnail
Do we need PCSK9 inhibitors in post-MI patients?

The Event

Event poster

ESC Congress 2017

27 August 2017 11:35 CET
You may be interested in
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Congress Presentation
A global perspective on lipid control after acute coronary syndrome: are we doing enough?
15 March 2025
thumbnail
Congress Session
Cholesterol efflux explained: a potential role in clinical outcomes
26 August 2022
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources